UK's Nissan Backing Shows Starmer's Push to Save Industrial Jobs
The prospect of new support from the UK government for Nissan Motor Co. is the latest sign of Prime Minister Keir Starmer's push to protect Britain's industrial base as he tries to stave off a political threat from Nigel Farage's Reform party and preserve the Japanese automaker's famous Sunderland plant.
Nissan's plan to issue a £1 billion ($1.3 billion) syndicated loan backed by UK Export Finance, a government agency, as part of a wider fund-raising effort marks a fresh case of the British state standing ready to aid the carmarker, which employs more than 6,000 workers at the Sunderland plant producing the Qashqai and Juke models. Nissan is the biggest employer in Sunderland, a Labour stronghold where Farage's upstart populist party has made inroads.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
'Dodgy Maths': Farage Slammed After True Cost Of 'DEI' Government Programmes Revealed
Nigel Farage has been accused of 'dodgy maths' after a £7 billion black hole in his spending plans was revealed. The Reform UK leader claimed he would be able to save that much every year by scrapping government 'diversity, equity and inclusion' (DEI) schemes. He said that would then go towards funding his party's plans to re-instate winter fuel payments, lift the two-child benefit cap and cut taxes. Speaking at an event in Westminster on Tuesday, Farage said DEI was 'estimated to cost government £7 billion every year'. But figures revealed by the Cabinet Office show that the actual amount spent by the civil service on those schemes in 2022/23 was just £27.1 million. A Cabinet Office source said: 'Nigel Farage's dodgy maths would be no joke for families. Like Liz Truss, he'd send a wrecking back through the economy, leaving working people to pick up the bill.' Farage has come in for widespread criticism after unveiling his spending plans, with the Institute for Fiscal Studies saying his tax cut plans alone would cost up to £80 billion. In a speech on Thursday, Keir Starmer accused him of planning a 'mad experiment' with the UK economy. He said: 'Farage is making the exact same bet Liz Truss did – that you can spend tens of billions on tax cuts without a proper way of paying for it. 'And just like Truss, he is using your family finances, your mortgage, your bills as a gambling chip on his mad experiment. The result will be the same.' But Reform UK MP Sarah Pochin told GB News that the prime minister was 'scaremongering'. She said: 'By scrapping the DEI woke nonsense projects across the civil service, across businesses, we will save £35 billion.' Keir Starmer Says Nigel Farage Is Trying To 'Poison Our Politics' Keir Starmer Warns Nigel Farage's 'Mad Experiment' Would Ruin Economy Like Liz Truss Robert Jenrick Suggests Nigel Farage Is On Drugs For Wanting To Scrap Two-Child Benefit Cap
Bloomberg
27 minutes ago
- Bloomberg
Thames Water Enters Key Month to Hammer Out Terms of Rescue Deal
Thames Water's financial rescue is entering a decisive month, as suitors haggle over creditor losses and the future of the indebted utility. US infrastructure giant KKR & Co. and a group of the company's creditors including Silver Point Capital and Elliott Management are due to submit their plans for fixing Thames to regulator Ofwat by the end of Friday. Negotiations are expected to run throughout June with agreement in summer — but for that, the successful bidder will need to cut a deal with the debtholders that currently control the company on the scope of their losses.
Yahoo
28 minutes ago
- Yahoo
Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas
First-in-human trial is designed to determine recommended dose of IKS03, a CD19-directed antibody drug conjugate, for the subsequent dose-expansion IKS03 is Iksuda's second asset to begin clinical testing NEWCASTLE, England, May 30, 2025--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces the completion of dosing of its first patient with IKS03, a CD19-directed ADC, in a phase 1, first-in-human, clinical trial in patients with advanced B cell non-Hodgkin lymphoma. This first-in-human study ( will evaluate the safety, tolerability, preliminary antineoplastic activity, pharmacokinetics and pharmacodynamics of increasing dose levels of IKS03, and determine the recommended dose for dose-expansion. Efficacy will be further evaluated in disease-specific expansion cohorts. The study is currently enrolling patients across clinical sites in Italy, Spain, Australia, United States and Canada. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: "With the first patient successfully completing the safety evaluation period with IKS03, Iksuda demonstrates its continued commitment to drive its differentiated ADCs through clinical proof of concept, further solidifying our position as a clinical-stage ADC-focused company. Although there have been advances in the treatment of non-Hodgkin lymphoma in recent years, there remains a significant unmet patient need, and we hope that IKS03 will be able to build on the potential benefit-risk profile suggested by the data generated in preclinical studies." About IKS03 IKS03 is a best-in-class CD19-targeting ADC delivering a tumour-activated prodrug pyrrolobenzodiazepine (PBD) which was licensed from LigaChem Biosciences (formerly LegoChem Biosciences) ( Preclinical testing demonstrates best-in-class efficacy (vs in-clinic and marketed CD19-targeted therapies) in in vivo xenograft models and significantly raised maximum tolerated dose (MTD) in non-human primate disease models, demonstrating its potential to be the leading anti-CD19 therapy in B-cell cancers. About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. View source version on Contacts For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive OfficerTel: +44 (0) 191 6031680Email info@ FTI Consulting (Financial Media and IR) Simon Conway / Rob Winder / Amy ByrneTel: +44 (0) 020 3727 1000Iksuda@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
